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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S107differences were found between limbs for the external sagittal and
frontal plane moments at the hip joint, subjects demonstrated greater
external adduction moment at the knee of the SX side compared to the
NSX side (MD: 0.12  0.11 Nm/Kg, p¼.013, d¼1.09).
Conclusions: The Hip Harris Score, pain level, and abductor strength
suggest that the SX hip is more impaired than the NSX limb. Subjects
also ambulate with a compensatory lateral trunk lean toward the
affected limb, but continue to demonstrate greater adduction angles on
the SX limb during single limb stance. These movement abnormalities
may represent the primary movement impairments and may be related
to the unilateral hip abductor weakness observed in this sample.
Unilateral impairments may also contribute to the signiﬁcantly larger
knee adduction moment on the NSX limb.Figure 1. Average trunk lean angle (A) and hip frontal plane angle (B) during the
stance phase of gait for the surgical limb (solid black line) and non-surgical limb
(dashed red line). Positive angles represent lean toward the stance leg (A) and
adduction (B). Black-striped area represents the standard deviation for the surgical
limb. Red-squared area represents the standard deviation for the non-surgical limb.185
THE TRANSIENT EFFECTS OF COX-2 INHIBITOR ON OSTEOGENIC
DIFFERENTIATION IN CANINE BONE MARROW-DERIVED
MESENCHYMAL STEM CELLS
N. Oh, T. Sunaga, S. Kim, K. Hosoya, M. Okumura. Hokkaido Univ.,
Sapporo, Japan
Purpose: Nonsteroidal anti-inﬂammatory drugs (NSAIDs), especially
cyclooxygenase (COX)-2 inhibitors, are simple and effective analgesics
in orthopedic ﬁelds. Last decades, the effects of COX-2 inhibitor on bone
healing process have remained controversial, while rare clinical data
represent relationship between COX-2 inhibitor and bone healing. The
aim of this study was to assess the effects of COX-2 inhibitors, such as
carprofen (Cp) and meloxicam (Mx), on osteogenic differentiation of
canine bone marrow-derived mesenchymal stem cells (BMSCs).
Methods: Canine BMSCs were harvested from three one-year-old
female beagle dogs. Osteogenic differentiation of canine BMSCs was
induced by osteogenic medium containing dexamethasone (100 nM), b-
glycerophosphate (10 mM), ascorbic acid (50 mg/ml) and human
recombinant IL-1b (1 ng/ml) as an inﬂammatory stimulator. The
maximum concentration of Cp (10 mM) or Mx (10 mM) that had no effect
on cell viability was treated within short- and long-term of osteogenic
process. The mRNA expressions of osteoblastic marker, involving alka-
line phosphatase (ALP) and osteocalcin, and prostaglandin E2 receptor
subtypes, such as EP2 and EP4, were measured using quantitative
reverse transcription-polymerase chain reaction (qRT-PCR). For the
histological evaluation, ALP staining and von Kossa staining were
performed.
Results: Expressions of mRNA of ALP and osteocalcin were signiﬁcantly
suppressed by use of COX-2 inhibitors. Alkaline phosphatase staining
revealed that COX-2 inhibitors partially arrested early differentiation of
osteoblast lineage. However, gene expressions of EP2 and EP4 were up-
regulated under COX-2 inhibition, and delayed osteogenic differentia-
tion was gradually recovered after withdrawal of COX-2 inhibitors.
Calciﬁcation of matrix showed no signiﬁcant difference between short-
term treated group and control at the late period of osteogenic
differentiation.
Conclusions: These data suggest that canine BMSCs might have
potential to catch-up the osteogenic differentiation and to up-regulate
osteogenic gene expression after withdrawal of COX-2 inhibitors.186
IDENTIFICATION OF FIBROBLAST GROWTH FACTOR-18 AS
A MOLECULE TO PROTECT AND REGENERATE ARTICULAR CARTILAGE
Y. Mori y, T. Saito y, C. Ladel z, H. Guehring z, U-i. Chung y,
H. Kawaguchi y. y Faculty of Med., Univ. of Tokyo, Tokyo, Japan; zMerck
KGaA, Darmstadt, Germany
Purpose: Aiming at the disease-modifying treatment of osteoarthritis
(OA), we sought to identify genes that maintain the homeostasis of
adult articular cartilage and regenerate its lesions by gene expression
proﬁle analyses. The mechanisms of the identiﬁed molecule underlying
the protection and regeneration were further investigated.
Methods: To identify genes that have both protective and regenerative
effects on adult articular cartilage, we performed two sets of microarray
analyses. First, to select genes that work for maintenance of articular
cartilage, we compared gene expression proﬁles between adult artic-
ular (AA) and adult growth plate (AG) cartilages in 10-week-old rats.
Second, to ﬁnd genes that function for regeneration of articular carti-
lage, we compared the proﬁles between infant superﬁcial (IS) and infant
deep (ID) layers of epiphyseal cartilage in 6-day-old rats. For genes
which were up-regulated 10-fold both in AA than in AG and in IS than
in ID, we performed real-time RT-PCR for the conﬁrmation. In vivo
expression was examined by immunohistochemistry of articular and
growth plate cartilage of 14-week-old rats. The therapeutic effect of
intra-articular injection of sprifermin (recombinant human ﬁbroblast
growth factor 18 (FGF18)) was examined in the experimental OA model
by surgical induction of instability in the knee joints of adult rats. To
further learn the underlying mechanism, the protective ability of
articular cartilage was assessed by measuring the amount of sulfated
glycosaminoglycan (sGAG) released into the medium in the ex vivo
culture of bilateral femoral heads of 3-week-old mice using dimethyl-
methylene blue dye-binding assay. Proliferation and migration were
analyzed in the cultures of mouse articular chondrocytes using Cell
Counting Kit-8 and Oris Cell Migration assay systems, respectively.
Expression levels of catabolism-related factors (Mmp9, Mmp13,
Adamts4, Adamts5, Timp1, Timp2, and Timp3) and anabolism-related
factors (Col2a1 and aggrecan) in the cultures of mouse femoral heads
and mouse articular chondrocytes were analyzed by real-time RT-PCR.
Results: Microarray analyses revealed that 40 and 186 genes had 10-
fold higher expression ratios of AA/AG and IS/ID, respectively, and 16
genes showed 10-fold of both AA/AG and IS/ID ratios. The ratios of the
16 genes were conﬁrmed to be 10 fold by real-time RT-PCR analysis.
Among them three genes were expressed more strongly in AA than in
IS. In these three genes, FGF18 was the extracellular and secreted factor
of which the AA/AG ratio was the highest in the microarray analysis.
Immunohistochemistry showed that FGF18 was strongly expressed in
the articular cartilage chondrocytes of adult rats but was hardly
detected in the growth plate cartilage. In the rat surgical OA model,
a once-weekly injection of sprifermin given 3 weeks post-surgery
prevented cartilage degeneration in a dose-dependent manner at 6 and
9 weeks after surgery, with a signiﬁcant effect at 10 mg/week of spri-
fermin. As an underlying mechanism, sprifermin suppressed the sGAG
release into the culture medium in the ex vivo culture of mouse femoral
heads. Furthermore, sprifermin accelerated proliferation and migration
of cultured mouse articular chondrocytes. Among catabolic and
anabolic factors, sprifermin decreased Adamts4 and increased Timp1
expressions in the cultures of mouse femoral heads and murine artic-
ular chondrocytes; however it decreased Col2a1 and aggrecan expres-
sions in both cultures.
Conclusions: The present gene expression proﬁling analysis identiﬁed
sprifermin as a molecule to protect and regenerate adult articular
cartilage, causing prevention of cartilage degeneration by the once-
weekly intra-articular injection in a rat model. This effect may be due to
inhibition of cartilage catabolism, and acceleration of proliferation and
migration of articular chondrocytes, providing a disease-modifying OA
treatment.
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OLD AND YOUNG ARTICULAR CARTILAGE RESPOND EQUIVALENTLY
FOR PHYSIOLOGICAL AND EXCESSIVE LOADING BY ACTIVATION OF
PROTECTIVE TGF-BETA SIGNALING
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